‘Insatiable’ demand drives up expectations for Catalent's gene therapy unit 03-Dec-2019 By Nick Taylor Analyst increases estimate of revenue potential of Catalent’s gene therapy unit in light of ‘insatiable’ demand.
Paragon contracted to support Amicus’ preclinical gene therapy program 04-Jul-2019 By Maggie Lynch Amicus and Paragon enter a preclinical manufacturing agreement for the former’s lysomal disorder programs currently in development at Penn.
People on the Move: Outsourcing-Pharma roundup March ‘19 29-Mar-2019 By Melissa Fassbender The industry in March saw new c-suite appointments at CRF Bracket, PCI Pharma Services, George Clinical, and Paragon Bioservices – as well as moves to boost medical device and DMPK services at Premier Research and Sygnature Discovery, respectively.